Monoclonal antibody therapy in cancer: When two is better (and considerably more expensive) than one

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• The US Food and Drug Administration approved the first monoclonal anticancer antibody, trastuzumab, 20 years ago.
• Monoclonal antibody therapy for cancer often faces challenges with partial responses and tumor resistance.
• Concurrent treatment with synergistic monoclonal antibodies is an emerging strategy to enhance therapeutic efficacy.

Purpose of the Study:

• To review the rationale and evidence for using combinations of monoclonal antibodies in cancer treatment.
• To discuss potential hazards, particularly autoimmune toxicities, associated with combination antibody therapy.
• To highlight the need for optimized treatment strategies to manage immune system overstimulation.

Main Methods:

• Review of existing literature on combination monoclonal antibody therapy in oncology.
• Analysis of clinical examples, including HER2-targeted antibodies for breast cancer and T-cell targeting antibodies for melanoma.
• Evaluation of the risks and benefits of combining different monoclonal antibodies for cancer treatment.

Main Results:

• Combination therapy with two monoclonal antibodies targeting distinct sites of HER2 has shown efficacy in breast cancer.
• Combining antibodies against two distinct T-cell antigens is a strategy for melanoma treatment.
• Concurrent antibody therapy can improve clinical responses and overcome resistance compared to monotherapy.

Conclusions:

• Combination monoclonal antibody therapy offers a promising strategy to improve cancer treatment outcomes.
• Careful research, biomarker development, and individualized therapy are crucial for optimizing combination treatments.
• Minimizing the risk of immune system overstimulation and associated toxicities is essential for safe and effective combination antibody therapy.